0 Hyaline articular and fibrocartilage, tendon, and ligament in organ culture release PPi into the ambient medium.9 10 Basal PPi release is stimulated twofold or more by transforming growth factor 1B (TGF,B) or ascorbate, and this increase is inhibited by probenecid, insulin-like growth factor, or inhibitors of protein synthesis.'1-14 In organ culture, normal human cartilage produced on average 2-5 pmol of PPi/mg/h.9 Measurements of joint surfaces in an anatomical skeleton showed that normal human knee contains about 37 g of cartilage (hyaline plus fibrous: unpublished data). This mass of tissue should generate approximately 0-08 ,umol of PPi per hour if the in vitro production rate is assumed.
* Injection of radiolabelled PPi and inorganic phosphate into human knee joints permitted calculation of the intrasynovial PPi pool and its rate of turnover.'5 Clearance of both nuclides was linear for three hours, implying a single kinetic compartment the mean volume of which exceeded that of the joint fluid by about 30 ml. Approximately 0 1 pumol of PPi was produced per hour by knees with normal radiographs, increasing to about 0-8 ,umol/ h in severely degenerated knees. The demonstration of a single PPi pool that included synovial fluid should have suggested to us that this compartment might contain both enzyme and substrate for PPi generation. PPi production calculated from kinetic studies (0-1 ,mol/h) closely approximates that extrapolated from in vitro release of PPi (0-08 ,umol/h).
* An enzyme, nucleoside triphosphate pyrophosphohydrolase (NTPPPHase), found in articular cartilage detergent extracts, was shown to hydrolyse ATP and other nucleotides to PPi:16
The reaction may be-driven to the right by removal of the PPi coproduct (AMP) by 5'nucleotidase. The activity of the enzyme was greatest in cartilage containing CPPD crystals, and virtually all the activity was outside the chondrocyte (that is, it was an ectoenzyme)." ATP added to chondrocytes in monolayer culture or cartilage slices in organ culture was preferentially hydrolysed to extracellular PPi.18 Chondrocytes depleted of NTPPPHase elaborated little measurable ppi.l7 19 There is now evidence for three ectoNTPPPHases. One, termed PC-1, was originally-isolated from a plasmacytoma cell line, and has been cloned and sequenced.20 It 30 seconds in CPPD fluids, and 86 seconds in one normal fluid.27 When ATP was infused into such fluids at rates intended to mimic steady state levels, it was converted preferentially to PPi (60-83%).27 Synovial fluid was as effective as whole cartilage in generating ATP from extracellular ATP, as would be predicted from the kinetic in vivo studies that indicated a single kinetic compartment for PPi production. Using the previously determined mean in vivo PPi pool size (approximately 50 ml), '5 we estimated that total PPi production by degenerated human knees would be 0-3-1 75 ,umol/h. The greatest estimated production rates were found in cases of severely degenerated joints containing CPPD crystals. These estimates, although admittedly crude, are consistent with the estimates of PPi production based on in vitro PPi generation by human cartilage organ cultures, and with rates calculated directly from in vivo radiolabelled PPi pool and turnover studies. Collectively, the data suggest that the measured PPi production in joint tissues compares quantitatively with estimates of PPi generation from extracellular ATP via ectoNTPPPHases. As it is likely that this process is substrate driven, we are actively seeking the source(s) of extracellular, intra-articular ATP.
0 Vesicles derived from chondrocytes are rich in NTPPPHase and are able to nucleate and grow monoclinic CPPD crystals in the presence of ATP.28 Moreover, ATP added to cartilage explants likewise induced the formation of perichondral CPPD-like crystals. 29 Clearly, both normal and abnormal joint tissues generate extracellular PPi. As this molecule is a potent inhibitor of apatite crystal nucleation and growth, we speculate that non-bony joint tissues require PPi to prevent ossification. Excess production of this inhibitor may result in the sporadic variety of CPPD crystal formation.
Unlike gout, a disease generally associated with a systemic abnormality of excess anion (hyperuricaemia), CPPD crystal deposition is driven by a local abnormality of excess articular anion production. In either condition, local factors determine the foci of crystal deposition. Local factors favouring CPPD crystal deposition could include bursts of increased PPi generation by selected chondrocytes, leading to a pericellular increase in anion; or chondrocytes may synthesise molecules or particulates capable of heterologous CPPD crystal nucleation.
CPPD crystals, in common with other crystals containing calcium, have potent, predictable, dose dependent, biological effects on synovial cells, macrophages, and chondrocytes.30 These effects include stimulation of neutral protease synthesis, arachidonic acid metabolism, inosinic acid metabolism, and growth factor activity, and occur in the presence of concentrations of crystals known to exist in synovial fluid. Pharmacological control of excess PPi levels may prevent CPPD crystal deposition much as control of excess urate prevents MSU crystal deposition in gout. Such control is our goal.
